Multi-strange particle production in relativistic heavy ion collisions at sNN=62.4\sqrt{s_{NN}}=62.4 GeV

We present preliminary STAR results on measurements of multi-strange particles $\Xi$, $\Omega$ and their anti-particles from Au+Au and Cu+Cu at $\sqrt{s_{NN}}=62.4$ GeV collisions. In order to better understand the role of strangeness enhancement in nucleus-nucleus collisions and its scaling properties with system size, we compare the results from Au+Au and Cu+Cu reactions for different event centrality classes. Strangeness enhancement is discussed in the context of multi-strange to pion ratios. Finally, $\Omega/\phi$ ratio is shown for different systems and energies for a systematic study

Measuring beauty production in Pb-Pb collisions at the LHC via single electrons in ALICE

We present the expected ALICE performance for the measurement of the p_t-differential cross section of electrons from beauty decays in central Pb-Pb collisions at the LHC.Comment: 4 pages, 2 figures, proceeding of poster presentation at "Quark Matter 2005

Recent Results on Strangeness Production at RHIC

Due to its large acceptance, the STAR experiment has acquired a wealth of data on strangeness production for a variety of collisions systems and energies, from p+p to Au+Au. By using the yields and spectra, we address the evolution of the bulk system, including strangeness enhancement and the flavour dependence of radial and elliptic flow. Utilising the fact that we can identify strange baryons and mesons, we investigate different hadronization mechanisms in the intermediate and high p$_{T}$ regions. The ratios of the particle yields, measured to high p$_{T}$, are used to further investigate the range and applicability of the previously reported anomalous baryon production. We also study two-particle azimuthal correlations of identified particles in order to investigate any flavour dependence of jet fragmentation in the available p$_{T}$ range. Data was presented for a number of different collision systems and energies.Comment: Proceedings of SQM'06 Conference, LA, 2006 (submitted to J. Phys. G

Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies

Monocyte-derived macrophages (M/M) are considered the second cellular target of HIV-1 and a crucial virus reservoir. M/M are widely distributed in all tissues and organs, including the CNS, where they represent the most common HIV-infected cells. Differently from activated CD4+ T lymphocytes, M/M are resistant to the cytopathic effect of HIV and survive HIV infection for a long lime. Moreover, HIV-1 replication in M/M is a key pathogenetic event during the course of HIV-1 infection. Overall findings strongly support the clinical relevance of anti-HIV drugs in M/M. Nucleoside RT inhibitors (NRTIs) are more active against HIV in M/M than in CD4+ T lymphocytes. Their activity is further boosted by the presence of an additional monophosphate group (i.e., a phosphonate group, as in the case of Tenofovir), thus overcoming the bottleneck of the low phosphorylation ability of M/M. In contrast, the antiviral activity of non-NRTIs (not affecting the DNA chain elongation) in M/M is similar to that in CD4+ T lymphocytes. Protease inhibitors are the only clinically approved drugs acting at a late stage of the HIV lifecycle. They are able to interfere with HIV replication in HIV-1 chronically infected M/M, even if at concentrations greater than those observed in HIV-1 chronically infected CD4+ T lymphocytes. Finally, several new drugs have been shown to interfere efficiently with HIV replication in M/M, including entry inhibitors. A better understanding of the activity of the anti-HIV drugs in M/M may represent a key element for the design of effective anti-HIV chemotherapy. © Society for Leukocyte Biology